The temporal relationship between preeclampsia and heart failure

Charlotte Baker, DrPH, MPH, CPH¹, Peter D Smits, PhD¹, Patricia Rodriguez, PhD¹, Brianna M Goodwin Cartwright, MS¹, Samuel Gratzl, PhD¹, Rajdeep Brar, MD¹, Emily Garrett, MD², and Nicholas L Stucky, MD, PhD¹

> ¹Truveta, Inc, Bellevue, WA ²Providence Medical Group, Renton, WA ^{*}nicholass@truveta.com

Corresponding author:

Dr Nicholas Stucky Truveta, Inc 1745 114th Ave SE, Bellevue, WA 98004 Email: nicholass@truveta.com

Keywords: Maternal Health, Health Disparities, Heart Failure, Hypertensive Disorders of Pregnancy, Preeclampsia

Key Points:

Question: Does having preeclampsia increase the rate of heart failure at or after delivery across demographics and obstetrics related comorbidities?

Findings: In this retrospective cohort study that included 718,166 deliveries, the risk of heart failure at any point after delivery was 2.82 times greater in women that had preeclampsia than those that did not, after controlling for obstetric comorbidities, race, ethnicity, and age.

Meaning: Regular long term clinical follow up or screening of women with preeclampsia for heart failure may be warranted.

Abstract

Importance: Hypertensive disorders of pregnancy (e.g., preeclampsia) occur in approximately 8 to 10% of pregnancies in the US. Preeclampsia is a significant risk factor for future cardiovascular disease but in the US there is no universal long-term clinical follow up or screening for these conditions.

Objective: To determine whether having preeclampsia increases the rate of heart failure at or after delivery across demographics and obstetrics related comorbidities.

Design: Retrospective cohort study. We examined deliveries between January 1, 2018 and March 31, 2023 and assessed the time to heart failure stratified by preeclampsia status. Index event (T0) was first recorded delivery in time frame.

Setting: Population based using nationally representative data from electronic health records by Truveta

Participants: Female. 16 to 50 years of age. First recorded delivery in time frame identified using ICD-9-CM, ICD-10-CM, and SNOMED CT codes for delivery. Exclusion criteria: missing information on sex, race, ethnicity, age; if last contact with the health care system was T0; recent history of related cardiovascular conditions; or congenital heart disease.

Exposure: Preeclampsia on or before delivery.

Main Outcomes and Measures: Diagnosis of heart failure (HF) at or after T0. Other measures included were Leonard's obstetric comorbidity score, age, race, ethnicity, and disability. We used Cox proportional hazards models to assess time till HF.

Results: 718,166 individuals were included and 14,204 had preeclampsia. After adjusting for obstetric comorbidities, race, ethnicity, age and disability, Black patients had a higher hazard of HF compared to white women (HR 3.48; CI 2.97, 4.06). Black patients with preeclampsia had a higher hazard of HF than white patients without preeclampsia (HR 4.63; CI 1.65, 12.99). Black patients without preeclampsia had a risk of HF similar to other racial groups with preeclampsia.

Conclusions and Relevance: The risk for HF after preeclampsia was significant and should continue to be explored. Modifiable factors for both preeclampsia and HF which should be a focus include substance use disorder and pregestational diabetes. Regular long term clinical follow up or screening of women with preeclampsia for HF may be warranted.

1 Introduction

There are higher rates of poor maternal health outcomes in the US than in other high income coun-2 tries 1^{-3} and these geographic disparities have only increased in the last decade $4^{,5}$. These maternal 3 health outcomes are driven by a number of factors including social determinants of health, commu-4 nity resources, clinical practices, and individual behaviors $^{6-8}$. Legal restriction on the availability 5 of elective pregnancy termination $^{9-11}$, diminishing availability of obstetric care even in urban ar-6 eas^{12-14} , and bias against patients in medicine^{15-17} are maternal health concerns most visible in 7 US media. There is a need to identify and address these issues of maternal health concern in order 8 to reverse these disparities and improve overall maternal health outcomes in the US. g One specific issue of concern is the incidence and subsequent health problems related to hy-10

¹⁰ One specific issue of concern is the incidence and subsequent hearth problems related to hy-¹¹ pertensive disorders of pregnancy (HDP), namely preeclampsia and gestational hypertension, that ¹² occur in approximately 8 to 10% of pregnancies in the US^{18,19}. Preeclampsia, a pregnancy related ¹³ condition characterized by high blood pressure, occurs most often during a person's first preg-¹⁴ nancy^{20,21}. More than 80% of pregnancies have at least one risk factor for HDP¹⁸ such as age, ¹⁵ pregestational hypertension, and pregestational diabetes^{20,22,23}. Preeclampsia can cause maternal ¹⁶ seizure (eclampsia), stroke, hemorrhage, kidney and cardiac injury.

A type of cardiovascular disease, heart failure (HF), has been connected to having preeclampsia²⁴⁻²⁷. HF risk factors are often preventable and modifiable but HF is not typically considered
a potential health problem of otherwise healthy women of childbearing age. Recent work has suggested that women with HDP during or after pregnancy are at greater risk for having HF within
and after 90 days post-pregnancy²⁵.

The purpose of this study is to determine whether having a diagnosis of preeclampsia or eclampsia (referred to hereforth as preeclampsia) at or before delivery increases the rate of HF after delivery across age, race, and ethnicity demographic characteristics and obstetrics related comorbidities.

25 Methods

²⁶ Data Source

Clinical data was compiled from a subset of Truveta data and consisted of de-identified medical 27 records representing ambulatory centers, hospitals, imaging centers, and clinics and medical of-28 fices. Truveta (https://www.truveta.com/) provides access to continuously updated and linked 29 electronic health records (EHR) and claims data including demographics, diagnoses, encounters, im-30 munizations, medications, laboratory results, procedures, clinical notes, and images. Truveta Data 31 used in this study was accessed on 2023-07-25. Through syntactic normalization, similar data fields 32 from different health care organizations are mapped to a common schema referred to as the Tru-33 veta Data Model (TDM). Once organized into common fields, the values are normalized to common 34 ontologies such as ICD-10, SNOMED-CT, LOINC, RxNorm, and CVX, through semantic normal-35 ization. The normalization process employs an expert-led, artificial intelligence driven process to 36 accomplish high-confidence modeling at scale. This study performs analysis of de-identified EHR 37 data accessed via Truveta Studio. Truveta Studio only contains data that has been de-identified by 38 expert determination in accordance with HIPAA Privacy Rule, and therefore this study was exempt 39 from Institutional Review Board approval. Truveta data has been used in previous research^{28–30} 40 and is available to all Truveta subscribers at (https://studio.truveta.com). 41

42 Study design and population

⁴³ This observational cohort study follows the STROBE reporting guideline³¹.

44 Eligibility criteria

Eligible female patients had a delivery between January 1, 2018 and March 31, 2023 and were
16 to 50 years of age. If patients had multiple deliveries within the time period, only the first
was included. Patients were identified using ICD-9-CM, ICD-10-CM, and SNOMED CT codes for
delivery (Supplement). The first delivery in the dataset was considered the index event, or time
zero (T0).

Patients were excluded if they had missing information on sex, race, ethnicity, or age. Patients
 were also excluded if their last contact with the health care system was on the day of delivery.
 Consistent with previous literature, patients were excluded if they had congenital heart disease³²
 or a history of HF, chronic kidney disease, pulmonary embolism, myocardial infarction, cardiomy-

 $_{54}$ opathy, or ischemic heart disease less than a year prior to delivery 25 as identified by diagnostic or

⁵⁵ billing codes (Supplement).

56 Outcome

The outcome of interest was HF at or after T0. A binary yes/no HF variable was defined using ICD-9-CM, ICD-10-CM, and SNOMED CT codes.

59 Exposure

⁶⁰ The exposure of interest was preeclampsia at or before T0. A binary yes/no variable for preeclampsia

⁶¹ was defined using ICD-9-CM, ICD-10-CM, and SNOMED CT codes.

62 Covariates

We used Leonard's validated obstetric comorbidity score³³ to control for indicators of severe ma-63 ternal morbidity during and after delivery. Included comorbidities and the method to calculate the 64 score can be found elsewhere³³, but were identified using ICD-9-CM, ICD-10-CM, and SNOMED 65 CT codes (Supplement). We modified the obstetric comorbidity score to include eclampsia in 66 the severe preeclampsia category. Pregestational diabetes (type 1 and type 2), body mass index 67 $(BMI) \geq 40$, gestational diabetes, pregestational hypertension, and age were added to the model as 68 covariates in addition to their inclusion in the obstetric comorbidity score. Age was assessed cate-69 gorically (16-17, 18-24, 25-34, 35-44, and >45). Race was categorized as Black or African American 70 (henceforth referred to as Black), white, Asian, and other. Because of small population sizes that 71 complicate statistical modeling, the "other" is a composite category of individuals who were catego-72 rized by the health systems as "other", Native American and Alaska Native, or Native Hawaiian or 73 other Pacific Islanders. Ethnicity was a binary variable of Hispanic and/or Latino and not Hispanic 74 and/or Latino. We expanded Gleason's ICD-9-CM definitions of intellectual, physical, and sensory 75 disability³⁴ to include ICD-10-CM and SNOMED CT codes and created a binary yes/no disability 76 variable. 77

All medical definitions used in this study were reviewed and approved by a clinical informaticist.

79 Study Population Flowchart




Figure 1: Cohort flowchart for the study of the risk of heart failure after preeclampsia or eclampsia between January 1, 2018 and March 31, 2023 in a subset of Truveta data. All medical conditions and diseases identified using ICD-9-CM, ICD-10-CM, and SNOMED CT codes (See study supplement).

Statistical analysis

81 We calculated descriptive statistics to describe the study population. Due to right censoring, time

to HF was assessed using Cox proportional hazards models. We completed two sets of analyses using

the most recent encounter in the data as the censoring date. In the first, women were followed for
90 days until time of HF or their censoring, whichever occurred first. In the second, women were
followed until the end of the available data until time of HF or their censoring, whichever occurred

⁸⁶ first. We plotted Kaplan-Meier curves of time to HF stratified by preeclampsia status and race.

For the survival analysis, all categorical covariates with more than 2 levels were transformed into multiple indicator variables, or dummy coded, with the most frequently occurring state being the reference state. Our first model included all of the covariates as additive effects, while our second model considered interaction terms between preeclampsia and race, preeclampsia and substance use

⁹¹ disorder, preeclampsia and disability, substance use disorder and race, and disability and race.

All models were fit using the survival R package^{35,36}. We compared these models using Akaike Information Criterion (AIC)³⁷, where the selected final model was that which had the lowest AIC value.

⁹⁵ We used the final model to estimate model based hazard ratios comparing different combinations ⁹⁶ of preeclampsia, race (white or Black), substance use disorder (Yes or No), and disability status (Yes ⁹⁷ or No). These hazard ratios were estimated from marginal means calculated using the **emmeans** R ⁹⁸ package³⁸. This approach accounts for interaction effects which prevent the simple exponentiation ⁹⁹ of the regression coefficients and provides interpretable results. Statistical significance (α =0.05) ¹⁰⁰ of specific variables was determined using confidence intervals (not inclusive of 1.0) and p-values

101 < 0.05).

¹⁰² Statistical programs and packages used

Statistical analysis was completed using Python and R software. Data preparation was completed
using Python 3.10.5^{39,40} and packages pandas^{41,42}, NumPy⁴³, PyYAML⁴⁴, and matplotlib⁴⁵. All
analyses were conducted in R Version 4.1.3⁴⁶ using packages dplyr⁴⁷, ggplot2⁴⁸, janitor⁴⁹,
gtsummary⁵⁰, broom⁵¹, emmeans³⁸, scales⁵², MASS⁵³, xtable⁵⁴, etm⁵⁵, survival^{35,36}, and survminer⁵⁶.
The study population flowchart was made using R Version 4.2.3 and packages xml2⁵⁷, DiagrammeR⁵⁸,
DiagrammeRsvg⁵⁹, and rsvg⁶⁰.

109 Results

¹¹⁰ Description of study patients

There were 1,021,660 patients 16 to 50 years of age that had pregnancy indicators or a delivery on 111 or after January 1, 2018 (Figure 1) that were considered for inclusion. Of that number, 303,493 112 people were excluded because of either 1) missing or unknown sex, race, ethnicity, and/or age; 2) 113 no contact with the health system after T0 or beyond the date the data were obtained for the study 114 (2023-07-25); 3) congenital heart disease; and/or 4) having a history of HF, chronic kidney disease. 115 pulmonary embolism, myocardial infarction, cardiomyopathy, or ischemic heart disease between 0 116 and 365 days prior to T0. A total of 718,166 people met the inclusion criteria and were included in 117 the study. 118

119 Demographics

A total of 14,204 patients had preeclampsia at or before delivery (Table 1; Figure 1) and 69 of these patients had HF at or after delivery. A total of 703,962 patients did not have preeclampsia

and 1,114 patients without preeclampsia were diagnosed with HF at or after delivery. Most people (57.3%) were between 25 and 34 years of age at the time of delivery. Black patients made up 13.7% of those without preeclampsia and 17.2% of those with preeclampsia. Asian patients made up 8.1% of those without preeclampsia and 6.4% of those with preeclampsia. White patients made up the majority of the study population (65.1%) and most of the study population was not Hispanic or Latino (81.1%).

32.1% of patients with preeclampsia and 2.0% of patients without preeclampsia had a preexisting heart condition at least a year before their delivery. These conditions included but were not
limited to hypertensive crisis, cardiac arrhythmia in childbirth, acute pericarditis, and hypertensive
chronic kidney disease (Table 1). The prevalence of pregestational hypertension was 1.1% of patients

without preeclampsia and 7.9% of patients with preeclampsia.

	No Preeclampsia/Eclampsia	Preeclampsia/Eclampsia	Overall
	(N=703,962)	$(N{=}14,204)$	(N=718,166)
Heart Failure Event		×	
No	702,848~(99.8%)	$14,135\ (99.5\%)$	$716,983\ (99.8\%)$
Yes	$1,114\ (0.2\%)$	69 (0.5%)	$1,183\ (0.2\%)$
Race	~	~	
Black	$96,499\ (13.7\%)$	$2,445\ (17.2\%)$	$98,944\ (13.8\%)$
Asian	57,221 $(8.1%)$	913 (6.4%)	$58,134 \ (8.1\%)$
White	458,193 $(65.1%)$	8,452 $(59.5%)$	466,645 $(65.0%)$
Other Race	$92,049\ (13.1\%)$	$2,394\ (16.9\%)$	$94,443\ (13.2\%)$
Ethnicity			
Hispanic or Latino	132,846~(18.9%)	2,973 $(20.9%)$	$135,819\ (18.9\%)$
Not Hispanic or Latino	571,116(81.1%)	11,231 $(79.1%)$	582,347 $(81.1%)$
Age Group			
0-17	$7,372\ (1.0\%)$	$104 \ (0.7\%)$	$7,476\ (1.0\%)$
18-24	$121,109\ (17.2\%)$	2,485 $(17.5%)$	$123,594\ (17.2\%)$
25-34	403,675 $(57.3%)$	7,756(54.6%)	411,431 $(57.3%)$
35-44	$160,597\ (22.8\%)$	3,733 $(26.3%)$	164,330 $(22.9%)$
≥ 45	$11,209\ (1.6\%)$	126(0.9%)	$11,335\ (1.6\%)$
Bleeding Conditions			
No	$692,071 \ (98.3\%)$	$13,591 \ (95.7\%)$	$705,662\ (98.3\%)$
Yes	11,891 $(1.7%)$	$613 \ (4.3\%)$	$12,504\ (1.7\%)$
Pregestational Diabetes			
No	$693,740\;(98.5\%)$	$13,556\ (95.4\%)$	$707,296\ (98.5\%)$
Yes	$10,222\ (1.5\%)$	$648 \ (4.6\%)$	$10,870\ (1.5\%)$
Gestational Diabetes			
No	$658,686 \ (93.6\%)$	$12,621\ (88.9\%)$	$671,307\ (93.5\%)$
Yes	45,276~(6.4%)	$1,583\ (11.1\%)$	$46,859\ (6.5\%)$
Pregestational Hypertension			
No	$696,451 \ (98.9\%)$	$13,076\ (92.1\%)$	$709,527\ (98.8\%)$
Yes	7,511 $(1.1%)$	1,128 $(7.9%)$	$8,639\ (1.2\%)$
Other Preexisting Cardiac Conditions			
No	690,070 $(98.0%)$	$9,645\ (67.9\%)$	699,715 $(97.4%)$
Yes	$13,892\ (2.0\%)$	4,559 $(32.1%)$	18,451 $(2.6%)$
Continued on next page			

Table1 – continued from previous page	ious page		
Feature	No Preeclampsia/Eclampsia Preeclampsia/Eclampsia Overal	Preeclampsia/Eclampsia	Overall
BMI ≥ 40			
No	(89,056 (97.9%))	13,424~(94.5%)	702,480 (97.8%)
Yes	14,906 (2.1%)	780(5.5%)	15,686 $(2.2%)$
Substance Use Disorder	~		
No	639,677 $(90.9%)$	$12,220\ (86.0\%)$	$651,897\ (90.8\%)$
Yes	64,285 $(9.1%)$	1,984 $(14.0%)$	66,269 $(9.2%)$
Disability			
No	$624,955\ (88.8\%)$	$12,036\ (84.7\%)$	$636,991 \ (88.7\%)$
Yes	79,007 (11.2%)	2,168 $(15.3%)$	81,175 $(11.3%)$
Obstetric Comorbidity Index			
Mean (SD)	$19.7\ (23.7)$	49.0(47.7)	$20.2 \ (24.8)$
Median [Min, Max]	12.0[0, 256]	38.0[0, 292]	$13.0 \ [0, \ 292]$
Table 1: D	Table 1: Demographic and comorbidity characteristics of people	acteristics of people	
that deliver	that delivered at or after January 1, 2018 to March 31, 2023 in a	March 31, 2023 in a	
subset of T	subset of Truveta data.		

¹³³ Time to heart failure after delivery

The differences in prevalence seen in Table 1 carried over to analyses of time to HF after delivery. 134 We used Kaplan-Meier curves to compare differences in patient time to HF at any point between 135 patients with preeclampsia and patients without preeclampsia (Figure 2 A) as well as time to HF 136 within 90 days of delivery (Figure 2 B). The prevalence of HF is small so the Y-axes in the graph 137 exclude 0-0.98 to highlight the differences. In both cases, there is a nearly immediate separation 138 in the curves and patients with preeclampsia have greater hazard of having the event of HF than 139 patients without preeclampsia. There were significant differences in time to HF stratified by race 140 (Figure 3) and disability (not shown) based on the Kaplan-Meier curves. The hazard of HF for 141 Black patients and Asian patients with and without preeclampsia approach each other between the 142 4- and 5-year marks. 143

¹⁴⁴ Multivariate time to event analysis

We selected the Cox proportional hazards model of time till HF which featured multiple interaction terms as our final model because it had a lower AIC (29491.4) than the model which had only additive effects among the covariates (29504.9) (Supplement). The interaction model was used for all subsequent hazard ratio calculations (Table 2, Table 3, Supplement).

Time to Heart Failure After Delivery by Preeclampsia Status

A. Survival Without Heart Failure Occurrence Any Time After Delivery




Figure 2: Time to Heart Failure After Delivery by Preeclampsia Status. Figure 2A displays the proportion of patients without heart failure at any point at or after delivery. Figure 2B displays the proportion of patients without heart failure within 90 days of delivery. In both figures (2A and 2B) the top line [green] is the proportion of patients without preeclampsia. The prevalence of HF is small so the Y-axes in the graph exclude 0-0.98 to highlight the differences. Graphs are not adjusted for additional factors.




Figure 3: Time to Heart Failure After Delivery by Preeclampsia Status and Race. Figure 3A displays the proportion of patients without heart failure at any point at or after delivery. Figure 3B displays the proportion of patients without heart failure within 90 days of delivery. In both figures (3A and 3B) the top line [green] is the proportion of patients without preeclampsia. The prevalence of HF is small so the Y-axes in the graph exclude 0-0.98 to highlight the differences. Graphs are not adjusted for additional factors.

Characteristic	$\mathbf{H}\mathbf{R}^1$	$95\% \ \mathrm{CI}^1$	p-value
Preeclampsia/Eclampsia			
No Preeclampsia/Eclampsia			
Preeclampsia/Eclampsia	2.81	1.91, 4.13	$<\!0.001$
Race		,	
White			
Black	3.48	2.97, 4.06	< 0.001
Asian	0.93	0.69, 1.25	0.6
Other Race	1.17	0.90, 1.53	0.2
Ethnicity		,	
Not Hispanic or Latino			
Hispanic or Latino	0.78	0.62, 0.96	0.021
Age Group		,	
0-17			
18-24	1.82	0.67, 4.92	0.2
25-34	3.10	1.16, 8.28	0.024
35-44	4.64	1.73, 12.4	0.002
>45	7.21	2.61, 19.9	< 0.001
Pregestational Diabetes (Type 1 and Type 2)		- ,	
No			
Yes	1.82	1.40, 2.36	< 0.001
Gestational Diabetes		,	
No			
Yes	0.94	0.76, 1.17	0.6
Pregestational Hypertension		,	
No			
Yes	1.41	1.07, 1.87	0.016
Other Preexisting Cardiac Conditions		,	
No			
Yes	1.30	1.00, 1.69	0.049
$BMI \ge 40$,	
No			
Yes	2.04	1.65, 2.54	$<\!0.001$
Substance Use Disorder		,	
No			
Yes	1.83	1.49, 2.26	< 0.001
Disability		,	
No			
Yes	1.29	1.05, 1.57	0.014
Obstetric Comorbidity Index Score	1.01	1.00, 1.01	$<\!0.001$

Table 2: Hazard of heart failure after delivery for women with preeclampsia January 1, 2018 to March 31, 2023. 1 HR = Hazard Ratio, CI = Confidence Interval

Pree	Preeclampsia/Eclampsia	Ra	Race	Subst	Substance Use Disorder	Disal	Disabilities		
Z	D	Z	D	Z	D	Z	D	Hazard Ratio	[95%]
Yes	Yes	Black	White	N_{0}	No	No	N_0	1.65	[0.53, 5.11]
\mathbf{Yes}	Yes	Black	White	$\mathbf{Y}_{\mathbf{es}}$	Yes	N_{O}	N_{O}	0.97	[0.28, 3.43]
$\mathbf{Y}_{\mathbf{es}}$	${ m Yes}$	Black	White	N_0	No	$\mathbf{Y}_{\mathbf{es}}$	Yes	1.23	[0.35, 4.25]
Yes	Yes	Black	White	\mathbf{Yes}	Yes	\mathbf{Yes}	Yes	0.72	[0.20, 2.66]
Yes	No	Black	White	N_{0}	No	No	N_0	4.63	[1.65, 12.99]
$\mathbf{Y}_{\mathbf{es}}$	No	Black	White	$\mathbf{Y}_{\mathbf{es}}$	Yes	N_{O}	N_{O}	1.59	[0.33, 7.74]
$\mathbf{Y}_{\mathbf{es}}$	No	Black	White	N_0	No	$\mathbf{Y}_{\mathbf{es}}$	\mathbf{Yes}	1.92	[0.41, 9.07]
Yes	No	Black	White	\mathbf{Yes}	Yes	\mathbf{Yes}	Yes	0.66	[0.11, 3.90]
Yes	No	White	White	N_{O}	No	No	N_0	2.81	[1.33, 5.92]
\mathbf{Yes}	No	White	White	\mathbf{Yes}	Yes	N_0	N_{0}	1.63	[0.49, 5.47]
\mathbf{Yes}	No	White	White	N_{O}	No	$\mathbf{Y}_{\mathbf{es}}$	$\mathbf{Y}_{\mathbf{es}}$	1.56	[0.47, 5.23]
\mathbf{Yes}	No	White	White	\mathbf{Yes}	\mathbf{Yes}	$\mathbf{Y}_{\mathbf{es}}$	$\mathbf{Y}_{\mathbf{es}}$	0.91	[0.23, 3.60]
Yes	No	Black	Black	No	No	No	No	1.33	[0.48, 3.70]
\mathbf{Yes}	No	Black	Black	$\mathbf{Y}_{\mathbf{es}}$	Yes	N_{O}	N_{O}	0.78	[0.18, 3.34]
\mathbf{Yes}	No	Black	Black	N_0	No	$\mathbf{Y}_{\mathbf{es}}$	$\mathbf{Y}_{\mathbf{es}}$	0.74	[0.18, 3.12]
Yes	No	Black	Black	\mathbf{Yes}	\mathbf{Yes}	$\mathbf{Y}_{\mathbf{es}}$	\mathbf{Yes}	0.43	[0.08, 2.22]
No	No	Black	White	N_0	No	No	No	3.48	[2.57, 4.70]
No	No	Black	White	\mathbf{Yes}	Yes	N_{0}	N_{O}	2.05	[1.10, 3.83]
N_{O}	No	Black	White	N_{0}	No	$\mathbf{Y}_{\mathbf{es}}$	\mathbf{Yes}	2.59	[1.43, 4.67]
N_{O}	No	Black	White	\mathbf{Yes}	\mathbf{Yes}	\mathbf{Yes}	$\mathbf{Y}_{\mathbf{es}}$	1.52	[0.76, 3.06]
	Ĩ	able 3: I	Hazard ra	atios	Table 3: Hazard ratios associated comparisons between heart	ons b	etween	heart	
	fa	ilure and	different	comb	failure and different combinations of preclampsia/eclampsia sta-	psia/e	clampsi	a sta-	
	tu :	(V_{22}/N)	o), substa	ance u	tus (Yes/No), substance use disorder (Yes/No), physical disabil), phy	/Plaal di	isabil- The	
	IU St	v (res/lvc ate of eac) anu un sh of thes	eir mu	ny (res/ro) and onen interaction with race (withe/ black). The state of each of these variables is shown in the [N]nmerator and	willue, Ie [N]i	merato	r and	
]enomina	tor colum	ins be	Denominator columns beneath each variable name. Hazard ratio	name.	Hazard	ratio	
	IIS	provided	with 95%	confi	is provided with 95% confidence intervals.				

We found that the hazard of HF was greater in patients with preeclampsia during the index 149 pregnancy compared with patients that did not have preeclampsia after adjusting for multiple 150 factors including obstetric comorbidities, age, race, ethnicity, and BMI >40 (HR 2.81; CI 1.91, 151 4.13) (Table 2). Black women have 3.48 (CI 2.97, 4.06) times the hazard of HF compared to white 152 women (Table 2). Women with substance use disorder are 1.83 (CI 1.49, 2.26) times more likely 153 than women without substance use disorder to have HF after delivery (Table 2). Women with 154 disabilities have a higher hazard of HF (HR 1.29; CI 1.05, 1.57) than women without disabilities 155 (Table 2). 156

When specifically comparing Black and white women, we found that Black women without preeclampsia have a hazard of HF 3.43 (CI 2.57, 4.70) times greater after delivery than white women without preeclampsia (Table 3, Supplement). In our population, the hazard of HF after delivery for Black women with preeclampsia compared to white women without preeclampsia was 4.63 times greater but had a wide confidence interval (CI 1.65,12.99) (Table 3, Supplement). The hazard of HF for white women with preeclampsia compared to those without was 2.81 (CI 1.35, 5.92) (Table 3, Supplement).

164 Discussion

The purpose of this large retrospective cohort study was to determine whether having a diagnosis of 165 preeclampsia at or before delivery increases the risk of HF at or after delivery across demographics, 166 obstetrics related comorbidities, age, race and/or ethnicity. Even following resolution, preeclampsia 167 is a significant risk factor for future cardiovascular disease, but there is no regular implementation 168 of long term clinical follow up or screening in the US. Prior research has connected the risk of HF to 169 preeclampsia^{24–27}, but more information is needed to assess the role of disparities in this outcome. 170 In this study of 718,166 deliveries, the risk of HF at any point after delivery was greater in women 171 that had preeclampsia than those that did not, after controlling for obstetrics comorbidities, race, 172 ethnicity, and age. 173

The variables that we identified as the most important for the occurrence of HF are non-174 modifiable socio-demographic factors (e.g., race, ethnicity); and preventable or modifiable disease 175 (e.g., substance use disorder, BMI \geq 40, pregestational diabetes)(Table 2, Table 3, Supplement). 176 These findings are in line with previous research on preeclampsia¹⁸, HF²¹, and the combination 177 of the preeclampsia and HF²⁵. Despite our findings, however, the etiology of the occurrence of 178 HF after HDP, especially preeclampsia, is not completely explained. We identified pregestational 179 diabetes, substance use disorder, and disability as important risk factors for HF after delivery 180 (Table 2, Supplement). Despite a small number of cases of HF at or after delivery, we found that 181 the risk for HF after preeclampsia was significant for all women and should continue to be explored. 182 It was clear in this analysis that race was significantly associated with both the occurrence of 183 preeclampsia and the occurrence of HF when stratified by preeclampsia status. This was expected, 184 especially given known disparities in maternal health outcomes in the $US^{61,62}$ and poor health 185 outcomes for non-white populations in the US. Importantly, regardless of preeclampsia status, 186 Black patients have similar risk of HF 5 or more years after delivery. Black patients without 187 preeclampsia have risk of HF similar to other racial groups with preeclampsia. When considering HF 188 and preeclampsia comorbidities, disparate outcomes existed for women with preeclampsia compared 189 to those without preeclampsia within race categories. We also found that the risk of HF was 190 higher for non-white women with substance use disorder (Supplement). There is a demonstrated 191 connection between substance use disorder and HF hospitalizations⁶³. Programs already exist 192

to address substance use disorder in childbearing persons and their children⁶⁴), but these results indicate that more can be done. Our results suggest that the combined effect of substance use disorder and preeclampsia on HF should be consistently included in further research.

¹⁹⁶ Strengths and Limitations

We did not include tobacco use, income, insurance type, urban/rural locality, parity, or previous 197 preeclampsia, factors that are important in the discussion of HF after pregnancy. We also did 198 not include any pregnant people that were below age 16 despite teenagers being at greater risk 199 for preeclampsia than older persons. We did not include people that did not have a biological sex 200 of female in the EHR. This study did not include two important clinical variables - severity of 201 preeclampsia or gestational hypertension - outside of their inclusion in the obstetric comorbidity 202 index. We acknowledge that the study results may be different when stratified by the severity of 203 preeclampsia. We also measured pregnancy by using delivery as the indicator. This means that we 204 may have undercounted the number of pregnant people, underestimated the risk of HF in people 205 with preeclampsia, and underestimated the effect of repeat preeclampsia on risk of HF. We were 206 unable to estimate any differences in outcome associated with caregiver type (e.g., physician, nurse 207 practitioner, doula, midwife). 208

Our approach has multiple strengths. This study used a nationally representative dataset derived 209 from EHR. The results could be considered generalizable for patients aged 16 to 50 that were white, 210 Black, and Asian, but care should be given when applying these results to populations that are not 211 specified here such as Native Hawaiian or Pacific Islander. Another strength of this study is the 212 use of an obstetric specific comorbidity index over the Elixhauser or Charlson comorbidity indexes. 213 While not containing all possible comorbidities for pregnancy, the care given to include gestational 214 diabetes, advanced maternal age, placental abruption, anemia, and mental health issues among 215 others makes this index better suited to account for comorbidities that are present or co-occur 216 during pregnancy rather than those that occur with other life illnesses. 217

While using a large cohort is a strength, ours is subject to a variety of known limitations to EHR 218 data. We are only able to identify events that are captured by the constituent health care systems 219 that are a part of the Truveta member system. Events and comorbidity status may be misclassified 220 when captured outside of member healthcare systems. These are common and well understood 221 limitations associated with using EHR data^{65,66}. Finally, the number of exclusion criteria used in 222 this study dramatically decreased the number of patients with preeclampsia. This directly affected 223 the statistical outcomes of this study and may not represent the full effects of preeclampsia on HF 224 after delivery for women with existing heart issues or newly diagnosed pregestational hypertension. 225 Despite these limitations, our results still underscore the need to examine the relationship between 226 preeclampsia and HF. 227

228 Conclusion

The purpose of this large retrospective cohort study was to determine whether having a diagnosis of preeclampsia at or before delivery increases the risk of HF at or after delivery across demographics, obstetrics related comorbidities, age, race, and ethnicity. We found this to be the case for each of these factors. Regular long term clinical follow up or screening of women with preeclampsia for HF may be warranted. Future research should focus on the impact of obstetrics related comorbidities that are modifiable, the impact of society on these outcomes, the impact of parity and prior history of preeclampsia, and further examine the impact of different types of disability on the incidence of

HDP and/or HF in pregnant women. We expect that each of these factors will help explain more of the disparity and provide guidance for clinical intervention over time.

238 Acknowledgements

The authors thank the clinical informatics team for their assistance and input during the design
and development of this study. We also thank the Truveta communications team for their ongoing
support as we conduct research that saves lives with data.

242 Funding

²⁴³ This study was funded internally by Truveta Inc.

²⁴⁴ Competing Interests

All authors, with the exception of Dr. Emily K. Garrett, are employees of Truveta Incorporated.

²⁴⁶ Institutional Review Board Approval

This study performs analysis of de-identified electronic health records (EHR) data accessed via Truveta Studio. Truveta Studio only contains data that has been de-identified by expert determination
in accordance with HIPAA Privacy Rule, and therefore this study was exempt from Institutional Review Board approval.

251 Data Availability Statement

252 Code necessary to generate all analyses and figures is included in a GitHub repository (https: //github.com/Truveta/baker_et_al_preeclampsia_heart_failure).

254 References

- [1] Andreea A. Creanga, Cynthia J. Berg, Carla Syverson, Kristi Seed, F. Carol Bruce, and William M. Callaghan. Pregnancy-Related Mortality in the United States, 2006-2010. Obstetrics & Gynecology, 125(1), 2015. ISSN 0029-7844. URL https://journals.lww.com/green journal/Fulltext/2015/01000/Pregnancy_Related_Mortality_in_the_United_States
 ,.3.aspx.
- [2] Jamila Taylor, Anna Bernstein, Thomas Waldrop, and Vina Smith-Ramakrishnan. The Wors ening U.S. Maternal Health Crisis in Three Graphs, mar 2022. URL https://tcf.org/cont
 ent/commentary/worsening-u-s-maternal-health-crisis-three-graphs/?agreed=1&ut
 m_medium=email&utm_source=transaction.

 [3] Munira Z. Gunja, Evan D. Gumas, and Reginald D. Williams II. The U.S. Maternal Mortality Crisis Continues to Worsen: An International Comparison. 2022. doi: 10.26099/8VEM-FC65.
 URL https://www.commonwealthfund.org/blog/2022/us-maternal-mortality-crisis-continues-worsen-international-comparison. Publisher: Commonwealth Fund.

- [4] Donna Hoyert. Maternal mortality rates in the United States, 2021. Technical report, National
 Center for Health Statistics (U.S.), March 2023. URL https://www.cdc.gov/nchs/data/he
 stat/maternal-mortality/2021/maternal-mortality-rates-2021.htm.
- [5] U.S. Government Accountability Office. Maternal Health: Outcomes Worsened and Disparities
 Persisted During the Pandemic. Technical Report GAO-23-105871, October 2022. URL https:
 //www.gao.gov/products/gao-23-105871.
- [6] Ruofei Du, Mir M. Ali, Yi-Shan Sung, Ambrish A. Pandit, Nalin Payakachat, Songthip T. Ounpraseuth, Everett F. Magann, and Hari Eswaran. Maternal comorbidity index and severe maternal morbidity among medicaid covered pregnant women in a US Southern rural state. *The Journal of Maternal-Fetal & Neonatal Medicine*, 36(1):2167073, December 2023. ISSN 1476-7058. doi: 10.1080/14767058.2023.2167073. URL https://doi.org/10.1080/14767058
 279 .2023.2167073. Publisher: Taylor & Francis.
- [7] Felix M. Muchomba, Julien Teitler, and Nancy E. Reichman. Association Between Housing Affordability and Severe Maternal Morbidity. JAMA Network Open, 5(11):e2243225-e2243225, November 2022. ISSN 2574-3805. doi: 10.1001/jamanetworkopen.2022.43225. URL https: //doi.org/10.1001/jamanetworkopen.2022.43225.
- [8] Meghan Tipre, Bolanle Bolaji, Christina Blanchard, Alex Harrelson, Jeff Szychowski, Rachel
 Sinkey, Zoe Julian, Alan Tita, and Monica L. Baskin. Relationship Between Neighborhood
 Socioeconomic Disadvantage and Severe Maternal Morbidity and Maternal Mortality. *Ethnicity & disease*, 32(4):293–304, 2022. ISSN 1945-0826 1049-510X. doi: 10.18865/ed.32.4.293. Place:
 United States.
- [9] Sara K. Redd, Kelli Stidham Hall, Monica S. Aswani, Bisakha Sen, Martha Wingate, and Whitney S. Rice. Variation in Restrictive Abortion Policies and Adverse Birth Outcomes in the United States from 2005 to 2015. Women's Health Issues, 32(2):103-113, March 2022. ISSN 1049-3867. doi: 10.1016/j.whi.2021.10.006. URL https://doi.org/10.1016/j.whi.2021.1
 0.006. Publisher: Elsevier.
- [10] Louise Marie Roth and Jennifer Hyunkyung Lee. Undue Burdens: State Abortion Laws in the
 U.S., 1994-2022. Journal of health politics, policy and law, page 10449905, January 2023. ISSN
 1527-1927 0361-6878. doi: 10.1215/03616878-10449905. Place: United States.
- [11] Eugene Declercq, Ruby Barnard-Mayers, Laurie Zephyrin, and Kay Johnson. The U.S.
 Maternal Health Divide: The Limited Maternal Health Services and Worse Outcomes of States Proposing New Abortion Restrictions. 2022. doi: 10.26099/Z7DZ-8211. URL
 https://www.commonwealthfund.org/publications/issue-briefs/2022/dec/us-mat
 ernal-health-divide-limited-services-worse-outcomes. Publisher: Commonwealth
 Fund.

- [12] C. Brigance, R. Lucas, E. Jones, A. Davis, Oinuma, and Z. Henderson. Nowhere to Go:
 Maternity Care Deserts Across the US. Technical Report 3, March of Dimes, 2022. URL
 https://www.marchofdimes.org/research/maternity-care-deserts-report.aspx.
- [13] Michael Ollove. A Shortage in the Nation's Maternal Health Care, August 2016. URL http: //pew.org/2boYfvJ.
- 308 [14] Centers for Medicare & Medicaid Services. Improving access to maternal health care in rural 309 communities. Technical report, 2020. URL https://www.cms.gov/About-CMS/Agency-Inf 310 ormation/OMH/equity-initiatives/rural-health/09032019-Maternal-Health-Care-i 311 n-Rural-Communities.pdf.
- [15] Esther H. Chen, Frances S. Shofer, Anthony J. Dean, Judd E. Hollander, William G.
 Baxt, Jennifer L. Robey, Keara L. Sease, and Angela M. Mills. Gender Disparity in Analgesic Treatment of Emergency Department Patients with Acute Abdominal Pain. Academic Emergency Medicine, 15(5):414-418, May 2008. ISSN 10696563, 15532712. doi:
 10.1111/j.1553-2712.2008.00100.x. URL https://onlinelibrary.wiley.com/doi/10
 .1111/j.1553-2712.2008.00100.x.
- [16] Northwell Health. Gaslighting in women's health: when doctors dismiss symptoms. URL
 https://www.northwell.edu/katz-institute-for-womens-health/articles/gaslighti
 ng-in-womens-health.
- [17] Calvin Apodaca, Reggie Casanova-Perez, Emily Bascom, Deepthi Mohanraj, Cezanne Lane,
 Drishti Vidyarthi, Erin Beneteau, Janice Sabin, Wanda Pratt, Nadir Weibel, and Andrea L
 Hartzler. Maybe they had a bad day: how LGBTQ and BIPOC patients react to bias in
 healthcare and struggle to speak out. Journal of the American Medical Informatics Association,
 29(12):2075-2082, December 2022. ISSN 1527-974X. doi: 10.1093/jamia/ocac142. URL
 https://doi.org/10.1093/jamia/ocac142.
- [18] Sarahn M. Wheeler, Sabrena O. Myers, Geeta K. Swamy, and Evan R. Myers. Estimated
 Prevalence of Risk Factors for Preeclampsia Among Individuals Giving Birth in the US in
 2019. JAMA Network Open, 5(1):e2142343-e2142343, January 2022. ISSN 2574-3805. doi:
 10.1001/jamanetworkopen.2021.42343. URL https://doi.org/10.1001/jamanetworkopen.
 2021.42343.
- [19] Nicole D. Ford, Shanna Cox, Jean Y. Ko, Lijing Ouyang, Lisa Romero, Tiffany Colarusso,
 Cynthia D. Ferre, Charlan D. Kroelinger, Donald K. Hayes, and Wanda D. Barfield. Hypertensive disorders in pregnancy and mortality at delivery hospitalization united states,
 2017-2019. MMWR. Morbidity and Mortality Weekly Report, 71(17):585-591, apr 2022. doi:
 10.15585/mmwr.mm7117a1. URL https://doi.org/10.15585%2Fmmwr.mm7117a1.
- ³³⁷ [20] National Institutes of Health. Who is at risk of preeclampsia?, June 2022. URL https:
 //www.nichd.nih.gov/health/topics/preeclampsia/conditioninfo/risk.

³³⁹ [21] US Preventive Services Task Force. Draft Evidence Review: Hypertensive Disorders of Preg ³⁴⁰ nancy: Screening, February 2023. URL https://www.uspreventiveservicestaskforce.or
 ³⁴¹ g/uspstf/document/draft-evidence-review/hypertensive-disorders-pregnancy-scr
 ³⁴² eening.

[22] Kirsten Duckitt and Deborah Harrington. Risk factors for pre-eclampsia at antenatal booking:
 systematic review of controlled studies. BMJ (Clinical research ed.), 330(7491):565, March
 2005. ISSN 1756-1833 0959-8138. doi: 10.1136/bmj.38380.674340.E0. Place: England.

- [23] Fred A. English, Louise C. Kenny, and Fergus P. McCarthy. Risk factors and effective management of preeclampsia. *Integrated blood pressure control*, 8:7–12, 2015. ISSN 1178-7104. doi: 10.2147/IBPC.S50641. Place: New Zealand.
- [24] Michael C. Honigberg. Understanding Heart Failure in Women With Preeclampsia. Journal of the American College of Cardiology, 78(23):2291-2293, December 2021. ISSN 07351097. doi: 10.1016/j.jacc.2021.09.1361. URL https://linkinghub.elsevier.com/retrieve/pii/S07 35109721077366.
- [25] Dominique Williams, Molly J. Stout, Joshua I. Rosenbloom, Margaret A. Olsen, Karen E.
 Joynt Maddox, Elena Deych, Victor G. Davila-Roman, and Kathryn J. Lindley. Preeclampsia
 Predicts Risk of Hospitalization for Heart Failure With Preserved Ejection Fraction. Journal
 of the American College of Cardiology, 78(23):2281–2290, December 2021. ISSN 07351097. doi:
 10.1016/j.jacc.2021.09.1360. URL https://linkinghub.elsevier.com/retrieve/pii/S07
 35109721077354.
- ³⁵⁹ [26] Mulubrhan F. Mogos, Mariann R. Piano, Barbara L. McFarlin, Jason L. Salemi, Kylea L. Liese, and Joan E. Briller. Heart Failure in Pregnant Women: A Concern Across the Pregnancy Continuum. *Circulation: Heart Failure*, 11(1):e004005, January 2018. ISSN 1941-3289, 1941-3297. doi: 10.1161/CIRCHEARTFAILURE.117.004005. URL https://www.ahajournals. org/doi/10.1161/CIRCHEARTFAILURE.117.004005.
- [27] Pensée Wu, Randula Haththotuwa, Chun Shing Kwok, Aswin Babu, Rafail A. Kotronias, Claire Rushton, Azfar Zaman, Anthony A. Fryer, Umesh Kadam, Carolyn A. Chew-Graham, and Mamas A. Mamas. Preeclampsia and Future Cardiovascular Health. *Circulation: Cardiovascular Quality and Outcomes*, 10(2):e003497, February 2017. doi: 10.1161/CIRCOUTCOMES.116.0
 03497. URL https://doi.org/10.1161/CIRCOUTCOMES.116.003497. Publisher: American Heart Association.
- Peter D. Smits, Samuel Gratzl, Michael Simonov, Senthil K. Nachimuthu, Brianna M. Goodwin Cartwright, Michael D. Wang, Charlotte Baker, Patricia Rodriguez, Mackenzie Bogiages,
 Benjamin M. Althouse, and Nicholas L. Stucky. Risk of COVID-19 breakthrough infection
 and hospitalization in individuals with comorbidities. Vaccine, 41(15):2447–2455, April 2023.
 ISSN 1873-2518. doi: 10.1016/j.vaccine.2023.02.038.
- Brianna M. Goodwin Cartwright, Michael Wang, Patricia Rodriguez, Sarah Stewart, Christopher M. Worsham, Nick Stucky, and Anupam B. Jena. Changes in Minoxidil Prescribing After
 Media Attention About Oral Use for Hair Loss. JAMA network open, 6(5):e2312477, May 2023. ISSN 2574-3805. doi: 10.1001/jamanetworkopen.2023.12477.
- [30] Benjamin M. Althouse, Charlotte Baker, Peter D. Smits, Samuel Gratzl, Ryan H. Lee, Brianna M. Goodwin Cartwright, Michael Simonov, Michael D. Wang, and Nicholas L. Stucky.
 Racial inequality in COVID-treatment and in-hospital length of stay in the US over time. Frontiers in Public Health, 10:1074775, 2022. ISSN 2296-2565. doi: 10.3389/fpubh.2022.1074775.

[31] Erik von Elm, Douglas G Altman, Matthias Egger, Stuart J Pocock, Peter C Gøtzsche, and Jan P Vandenbroucke. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *The Lancet*, 370(9596): 1453-1457, oct 2007. doi: 10.1016/s0140-6736(07)61602-x. URL https://doi.org/10.1016% 2Fs0140-6736%2807%2961602-x.

[32] Michael C. Honigberg, Seyedeh Maryam Zekavat, Krishna Aragam, Derek Klarin, Deepak L.
Bhatt, Nandita S. Scott, Gina M. Peloso, and Pradeep Natarajan. Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy. Journal of the American College of Cardiology, 74(22):2743-2754, December 2019. ISSN 0735-1097. doi: 10.1016/j.jacc.2019.09.0
URL https://www.sciencedirect.com/science/article/pii/S0735109719379197.

[33] Stephanie A. Leonard, Chris J. Kennedy, Suzan L. Carmichael, Deirdre J. Lyell, and Elliott K.
Main. An Expanded Obstetric Comorbidity Scoring System for Predicting Severe Maternal
Morbidity. Obstetrics and gynecology, 136(3):440–449, September 2020. ISSN 1873-233X 00297844. doi: 10.1097/AOG.00000000004022. Place: United States.

[34] Jessica L. Gleason, Jagteshwar Grewal, Zhen Chen, Alison N. Cernich, and Katherine L.
Grantz. Risk of Adverse Maternal Outcomes in Pregnant Women With Disabilities. JAMA *network open*, 4(12):e2138414, December 2021. ISSN 2574-3805. doi: 10.1001/jamanetworko
pen.2021.38414. Place: United States.

- [35] Terry M. Therneau and Patricia M. Grambsch. Modeling Survival Data: Extending the Cox
 Model. Springer, New York, 2000. ISBN 0-387-98784-3.
- [36] Terry M Therneau. A Package for Survival Analysis in R, 2023. URL https://CRAN.R-pro
 ject.org/package=survival. R package version 3.5-5.
- [37] Hirotugu Akaike. A new look at the statistical model identification. *IEEE transactions on automatic control*, 19(6):716–723, 1974.

[38] Russell V. Lenth, Ben Bolker, Paul Buerkner, Iago Giné-Vázquez, Maxime Herve, Maarten Jung, Jonathon Love, Fernando Miguez, Hannes Riebl, and Henrik Singmann. emmeans:
 Estimated Marginal Means, aka Least-Squares Means, March 2023. URL https://CRAN.R-p
 roject.org/package=emmeans.

- [39] Python Software Foundation. python, June 2022. URL https://www.python.org/.
- [40] Guido Van Rossum and Fred L. Drake. Python 3 Reference Manual. CreateSpace, Scotts
 Valley, CA, 2009. ISBN 1441412697. doi: 10.5555/1593511.

[41] Wes McKinney. Data Structures for Statistical Computing in Python. In Stéfan van der Walt
and Jarrod Millman, editors, *Proceedings of the 9th Python in Science Conference*, pages 56 –
61, 2010. doi: 10.25080/Majora-92bf1922-00a.

- [42] The pandas development team. pandas-dev/pandas: Pandas, jan 2023. URL https://doi.
 org/10.5281/zenodo.7549438. If you use this software, please cite it as below.
- [43] Charles R. Harris, K. Jarrod Millman, Stéfan J. van der Walt, Ralf Gommers, Pauli Virtanen, David Cournapeau, Eric Wieser, Julian Taylor, Sebastian Berg, Nathaniel J. Smith,

Robert Kern, Matti Picus, Stephan Hoyer, Marten H. van Kerkwijk, Matthew Brett, Allan Haldane, Jaime Fernández del Río, Mark Wiebe, Pearu Peterson, Pierre Gérard-Marchant, Kevin
Sheppard, Tyler Reddy, Warren Weckesser, Hameer Abbasi, Christoph Gohlke, and Travis E.
Oliphant. Array programming with NumPy. Nature, 585(7825):357–362, September 2020. doi:

- 425 10.1038/s41586-020-2649-2. URL https://doi.org/10.1038/s41586-020-2649-2.
- [44] Kirill Simonov. PyYAML, October 2021. URL https://pyyaml.org/wiki/PyYAMLDocument
 ation.
- [45] J. D. Hunter. Matplotlib: A 2d graphics environment. Computing in Science & Engineering,
 9(3):90–95, 2007. doi: 10.1109/MCSE.2007.55.
- [46] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, 2022. https://www.R-project.org/.
- [47] Hadley Wickham, Romain François, Lionel Henry, and Kirill Müller. dplyr: A Grammar of
 Data Manipulation, 2022. https://CRAN.R-project.org/package=dplyr.
- 434 [48] Hadley Wickham. ggplot2: Elegant Graphics for Data Analysis, 2016.
 435 https://ggplot2.tidyverse.org.
- [49] Sam Firke, Bill Denney, Chris Haid, Ryan Knight, Malte Grosser, and Jonathan Zadra. janitor:
 Simple Tools for Examining and Cleaning Dirty Data, February 2023. URL https://CRAN.R
 -project.org/package=janitor.
- [50] Daniel D. Sjoberg, Joseph Larmarange, Michael Curry, Jessica Lavery, Karissa Whiting,
 Emily C. Zabor, Xing Bai, Esther Drill, Jessica Flynn, Margie Hannum, Stephanie Lobaugh,
 Shannon Pileggi, Amy Tin, and Gustavo Zapata Wainberg. gtsummary: Presentation-Ready
 Data Summary and Analytic Result Tables, January 2023. URL https://CRAN.R-project.o
 rg/package=gtsummary.
- [51] David Robinson, Alex Hayes, Simon Couch [aut, cre, Posit Software, PBC, Indrajeet Patil, 444 Derek Chiu, Matthieu Gomez, Boris Demeshev, Dieter Menne, Benjamin Nutter, Luke John-445 ston, Ben Bolker, Francois Briatte, Jeffrey Arnold, Jonah Gabry, Luciano Selzer, Gavin Simp-446 son, Jens Preussner, Jay Hesselberth, Hadley Wickham, Matthew Lincoln, Alessandro Gas-447 parini, Lukasz Komsta, Frederick Novometsky, Wilson Freitas, Michelle Evans, Jason Cory 448 Brunson, Simon Jackson, Ben Whalley, Karissa Whiting, Yves Rosseel, Michael Kuehn, Jorge 449 Cimentada, Erle Holgersen, Karl Dunkle Werner, Ethan Christensen, Steven Pav, Paul PJ, Ben 450 Schneider, Patrick Kennedy, Lily Medina, Brian Fannin, Jason Muhlenkamp, Matt Lehman, 451 Bill Denney, Nic Crane, Andrew Bates, Vincent Arel-Bundock, Hideaki Hayashi, Luis Tobalina, 452 Annie Wang, Wei Yang Tham, Clara Wang, Abby Smith, Jasper Cooper, E. Auden Krauska, 453 Alex Wang, Malcolm Barrett, Charles Gray, Jared Wilber, Vilmantas Gegzna, Eduard Szoecs, 454 Frederik Aust, Angus Moore, Nick Williams, Marius Barth, Bruna Wundervald, Joyce Cahoon, 455 Grant McDermott, Kevin Zarca, Shiro Kuriwaki, Lukas Wallrich, James Martherus, Chuliang 456 Xiao, Joseph Larmarange, Max Kuhn, Michal Bojanowski, Hakon Malmedal, Clara Wang, Ser-457 gio Oller, Luke Sonnet, Jim Hester, Ben Schneider, Bernie Gray, Mara Averick, Aaron Jacobs, 458 Andreas Bender, Sven Templer, Paul-Christian Buerkner, Matthew Kay, Erwan Le Pennec, 459 Johan Junkka, Hao Zhu, Benjamin Soltoff, Zoe Wilkinson Saldana, Tyler Littlefield, Charles T. 460 Gray, Shabbh E. Banks, Serina Robinson, Roger Bivand, Riinu Ots, Nicholas Williams, Nina 461

Jakobsen, Michael Weylandt, Lisa Lendway, Karl Hailperin, Josue Rodriguez, Jenny Bryan, Chris Jarvis, Greg Macfarlane, Brian Mannakee, Drew Tyre, Shreyas Singh, Laurens Geffert, Hong Ooi, Henrik Bengtsson, Eduard Szocs, David Hugh-Jones, Matthieu Stigler, Hugo Tavares, R. Willem Vervoort, Brenton M. Wiernik, Josh Yamamoto, Jasme Lee, Taren Sanders, Ilaria Prosdocimi, Daniel D. Sjoberg, and Alex Reinhart. broom: Convert Statistical Objects into Tidy Tibbles, March 2023. URL https://CRAN.R-project.org/package=broom.

- 468 [52] Hadley Wickham and Dana Seidel. scales: Scale Functions for Visualization, 2020.
 https://CRAN.R-project.org/package=scales.
- [53] W. N. Venables and B. D. Ripley. Modern Applied Statistics with S. Springer, New York,
 fourth edition, 2002. URL https://www.stats.ox.ac.uk/pub/MASS4/.
- [54] David B. Dahl, David Scott, Charles Roosen, and Magnusson. *xtable: Export Tables to LaTeX* or HTML. 2019. URL https://CRAN.R-project.org/package=xtable.
- 474 [55] Mark Clements and Arthur Allignol. etm: Empirical Transition Matrix, September 2020. URL
 475 https://CRAN.R-project.org/package=etm.
- [56] Alboukadel Kassambara, Marcin Kosinski, and Przemyslaw Biecek. survminer: Drawing Survival Curves using 'ggplot2', 2021. URL https://CRAN.R-project.org/package=survminer.
 R package version 0.4.9.
- [57] Hadley Wickham, Jim Hester, and Jeroen Ooms. xml2: Parse XML, 2021. URL https:
 //CRAN.R-project.org/package=xml2. R package version 1.3.3.
- [58] Richard Iannone. DiagrammeR: Graph/Network Visualization, 2022. URL https://CRAN.R
 -project.org/package=DiagrammeR. R package version 1.0.9.
- [59] Richard Iannone. DiagrammeRsvg: Export DiagrammeR Graphviz Graphs as SVG, 2016. URL
 https://CRAN.R-project.org/package=DiagrammeRsvg. R package version 0.1.
- [60] Jeroen Ooms. rsvg: Render SVG Images into PDF, PNG, (Encapsulated) PostScript, or
 Bitmap Arrays, 2022. URL https://CRAN.R-project.org/package=rsvg. R package version
 2.4.0.
- [61] Jay J. Shen, Zahra Mojtahedi, Jennifer Vanderlaan, and Sfurti Rathi. Disparities in Adverse
 Maternal Outcomes Among Five Race and Ethnicity Groups. *Journal of women's health (2002)*,
 31(10):1432–1439, October 2022. ISSN 1931-843X 1540-9996. doi: 10.1089/jwh.2021.0495.
 Place: United States.
- [62] Jennifer D. Runkle, Jessica L. Matthews, Laurel Sparks, Leo McNicholas, and Margaret M.
 Sugg. Racial and ethnic disparities in pregnancy complications and the protective role of
 greenspace: A retrospective birth cohort study. *The Science of the total environment*, 808:
 152145, February 2022. ISSN 1879-1026 0048-9697. doi: 10.1016/j.scitotenv.2021.152145.
 Place: Netherlands.
- [63] Marin Nishimura, Harpreet Bhatia, Janet Ma, Stephen D. Dickson, Laith Alshawabkeh, Eric
 Adler, Alan Maisel, Michael H. Criqui, Barry Greenberg, and Isac C. Thomas. The impact of
 substance abuse on heart failure hospitalizations. *The American Journal of Medicine*, 133(2):
 207-213.e1, feb 2020. doi: 10.1016/j.amjmed.2019.07.017. URL https://doi.org/10.1016%
 2Fj.amjmed.2019.07.017.

[64] Keith A. Dookeran, Marina G. Feffer, Kyla M. Quigley, Phoebe E. Troller, Chariya A. Christmon, and Janine Y. Khan. Disparity in neonatal abstinence syndrome by race/ethnicity, socioeconomic status, and geography, in neonates ≥ 35 weeks gestational age. *PLOS ONE*, 18 (4):e0284040, apr 2023. doi: 10.1371/journal.pone.0284040. URL https://doi.org/10.137 1%2Fjournal.pone.0284040.

- ⁵⁰⁷ [65] Suchitra Kataria and Vinod Ravindran. Electronic health records: A critical appraisal of strengths and limitations. *Journal of the Royal College of Physicians of Edinburgh*, 50(3):
 ⁵⁰⁹ 262-268, sep 2020. doi: 10.4997/jrcpe.2020.309. URL https://doi.org/10.4997%2Fjrcpe.
 ⁵¹⁰ 2020.309.
- [66] Brent A. Williams, Stephen Voyce, Stephen Sidney, Véronique L. Roger, Timothy B. Plante,
 Sharon Larson, Michael J. LaMonte, Darwin R. Labarthe, Bailey M. DeBarmore, Alexander R.
 Chang, Alanna M. Chamberlain, and Catherine P. Benziger. Establishing a national cardiovascular disease surveillance system in the united states using electronic health record data:
 Key strengths and limitations. *Journal of the American Heart Association*, 11(8), apr 2022.
 doi: 10.1161/jaha.121.024409. URL https://doi.org/10.1161%2Fjaha.121.024409.